Karolinska’s Axelar comes up short in Phase II with lung cancer drug

Damian Garde

Swedish biotech 's failed to beat out standard docetaxel in a mid-stage trial, but bankroller Karolinska Development isn't giving up, planning to keep studying the in hopes of finding a partner.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS